Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products. The Lif… Read more
Genscript Biotech Corporation (GNNSF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.053x
Based on the latest financial reports, Genscript Biotech Corporation (GNNSF) has a cash flow conversion efficiency ratio of 0.053x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($232.62 Million) by net assets ($4.42 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genscript Biotech Corporation - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Genscript Biotech Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genscript Biotech Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genscript Biotech Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Busey Corporation
NASDAQ:BUSEP
|
0.029x |
|
FREEDOM HLDG DL-001
F:DMW2
|
N/A |
|
Diebold Nixdorf, Incorporated
NYSE:DBD
|
0.197x |
|
Sankyu Inc
F:SNK
|
N/A |
|
Shanghai Sinyang Semiconductor
SHE:300236
|
0.029x |
|
Minerals Technologies Inc
NYSE:MTX
|
0.041x |
|
Capri Holdings Ltd
NYSE:CPRI
|
1.874x |
|
Wihlborgs Fastigheter AB
ST:WIHL
|
0.020x |
Annual Cash Flow Conversion Efficiency for Genscript Biotech Corporation (2013–2024)
The table below shows the annual cash flow conversion efficiency of Genscript Biotech Corporation from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.32 Billion | $75.65 Million | 0.017x | +112.47% |
| 2023-12-31 | $2.04 Billion | $-286.91 Million | -0.140x | -58.98% |
| 2022-12-31 | $1.36 Billion | $-120.29 Million | -0.088x | +29.47% |
| 2021-12-31 | $1.09 Billion | $-136.79 Million | -0.125x | +32.44% |
| 2020-12-31 | $815.59 Million | $-151.09 Million | -0.185x | -130.25% |
| 2019-12-31 | $372.30 Million | $-29.95 Million | -0.080x | -113.44% |
| 2018-12-31 | $493.30 Million | $295.41 Million | 0.599x | +539.88% |
| 2017-12-31 | $228.32 Million | $21.37 Million | 0.094x | -48.24% |
| 2016-12-31 | $184.02 Million | $33.27 Million | 0.181x | +37.44% |
| 2015-12-31 | $149.25 Million | $19.64 Million | 0.132x | -33.44% |
| 2014-12-31 | $61.75 Million | $12.21 Million | 0.198x | -11.30% |
| 2013-12-31 | $53.95 Million | $12.02 Million | 0.223x | -- |